Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis
Sunhuan Zhang, Tongtong Cheng
Abstract
Background: Many studies have explored the value of the systemic inflammation response index (siRi) in predicting the prognosis of patients with breast cancer (Bc); however, their findings remain controversial.consequently, we performed the present meta-analysis to accurately identify the role of siRi in predicting Bc prognosis.Methods: PubMed, embase, cochrane library, and Web of science databases were comprehensively searched between their inception and February 10, 2024.the significance of siRi in predicting overall survival (Os) and disease-free survival (DFs) in Bc patients was analyzed by calculating pooled hazard ratios (hRs) and corresponding 95% confidence intervals (cis).Results: eight articles involving 2,997 patients with Bc were enrolled in the present study.according to our combined analysis, a higher siRi was markedly associated with dismal Os (hR = 2.43, 95%ci = 1.42-4.15,p < 0.001) but not poor DFs (hR = 2.59, 95%ci = 0.81-8.24,p = 0.107) in patients with Bc.Moreover, based on the pooled results, a high siRi was significantly related to t3-t4 stage (OR = 1.73, 95%ci = 1.40-2.14,p < 0.001), N1-N3 stage (OR = 1.61, 95%ci = 1.37-1.91,p < 0.001), tNM stage iii (OR = 1.63, 95%ci = 1.34-1.98,p < 0.001), and poor differentiation (OR = 1.25, 95%ci = 1.02-1.52,p = 0.028).Conclusion: according to our results, a high siRi significantly predicted poor Os in patients with Bc.Furthermore, elevated siRi was also remarkably related to increased tumor size and later Bc tumor stage.the siRi can serve as a novel prognostic biomarker for patients with Bc. KEY MESSAGESBased on our knowledge, this study is the first meta-analysis to explore value of siRi in predicting Bc prognosis.according to our results, a high siRi significantly predicted the dismal Os in Bc patients.siRi can serve as the novel prognostic biomarker for Bc patients.